China's pharmaceutical foreign trade expanded steadily in the first half of 2026, with total value reaching US$104.32 billion – a 6.4% year-on-year increase, according to customs data cited by China Pharmaceutical News (Aug 13, 2026). Exports grew at a faster clip of 9.9% to US$59.97 billion, signaling strong overseas demand.
Two trends stand out for suppliers like FS Pharma: medical devices (up 12.5%) and western pharmaceuticals (up 8.4%) led the pack, with disposable consumables surging 17.1%. This aligns with FS Pharma's own growth in vacuum blood collection tubes and essential biologicals.
FOSDHAN Pharma Perspective: The acceleration from 5.5% Q1 growth to 14% Q2 growth reflects not just seasonality but deepening market penetration in emerging economies. For our core products – tetanus antitoxin, rabies vaccines, and hepatitis vaccines – we see parallel demand surges in Africa and Southeast Asia, where public health spending is rising. The shift toward higher-value exports validates our strategy to emphasize biologicals over bulk APIs.
We interpret the data as a clear signal that global buyers increasingly trust Chinese pharmaceutical quality. FOSHAN Pharma's 20+ years of export experience position us to capture this upswing, especially in regions where we have established distributor networks.